First Trust TCW Unconstrained Plus Bond ETF UCON 深 滬
等待開盤 06-15 09:30:00 美东时间
24.90
-0.020
-0.08%
華盛通- 最 高24.92
- 今 開24.88
- 成交量 50.80万股
- 最 低 24.87
- 昨 收 24.92
- 總市值 32.81亿
- 52周最高 25.205
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 23.6101
- 委 比 26.74%
- 總股本 1.32亿
- 歷史最高 25.205
- 量 比 0.92
- 振 幅 0.20%
- 歷史最低 14.9998
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions
For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
05-07 14:02
Ducon Infratech Board Clears Capital Expansion and Promoter Loan-to-Equity Plan
The latest update is out from Ducon Infratechnologies Ltd. ( ($IN:DUCON) ). Duc...
04-26 17:12
Pharming granted EU backing for rare immunodeficiency therapy
Pharming Group (PHAR) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, issued a positive opinion recommending marketing authorization for Joenja, a tre...
03-28 00:10
Pharming Group NV Publishes Transcript of 4Q/FY 2025 Results Call
Pharming Group NV Publishes Transcript of 4Q/FY 2025 Results Call Pharming held a Q4 and full-year 2025 results call attended by CEO Fabrice Chouraqui, Chief Commercial Officer Leverne Marsh, Chief Medical Officer Anurag Relan and CFO Kenneth Lynard, with analysts including Lucy Codrington, Joseph P
03-19 17:54
Pharming beats top-line estimates; introduces FY26 outlook
Pharming press release (PHAR): Q4 GAAP EPS of $0.01 in-line. Revenue of $106.5M (+14.9% Y/Y) beats by $0.6M. RUCONEST® revenues amounted to US$86.7 million, a 9% increase compared to the fourth quarte...
03-12 14:33
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M
For 2026, the Company anticipates:Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
03-12 14:10
Pharming FY 2025 operating profit hits USD 25.8 million as total revenues rise 27% to USD 376.1 million
Pharming FY 2025 operating profit hits USD 25.8 million as total revenues rise 27% to USD 376.1 million Pharming reported Q4 2025 total revenues rose 15% to USD 106.5 million, driven by a 53% increase in Joenja revenue to USD 19.8 million on higher volume. FY 2025 total revenues increased 27% to USD
03-12 14:01
BRIEF-Subaru Of America Says Subaru Solterra EV Adds Tesla Supercharging Access Via Subaruconnect App
Oct 22 (Reuters) - Subaru Of America: SUBARU OF AMERICA: SUBARU SOLTERRA EV ADDS TESLA SUPERCHARGING ACCESS THROUGH SUBARUCONNECT APP SUBARU OF AMERICA: 2026 SUBARU SOLTERRA EV MODELS CAN USE PLUG & C...
2025-10-23 02:49
First Trust TCW Unconstrained Plus Bond ETF declares $0.11 dividend
First Trust TCW Unconstrained Plus Bond ETF (NYSEARCA:UCON) declares $0.11/share monthly dividend. Payable Nov. 17; for shareholders of record Nov. 3; ex-div Nov. 3. See UCON Dividend Scorecard, Yield...
2025-10-21 21:27
First Trust TCW Unconstrained Plus Bond ETF declares $0.095 dividend
First Trust TCW Unconstrained Plus Bond ETF (NYSEARCA:UCON) declares $0.095/share monthly dividend. Payable Sept. 30; for shareholders of record Sept. 25; ex-div Sept. 25. See UCON Dividend Scorecard,...
2025-09-25 23:05
